Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Ye Li, Katayoun Rezvani, Hind Rafei
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 217-235
Open Access | Times Cited: 20

Showing 20 citing articles:

CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Sunil Acharya, Rafet Başar, May Daher, et al.
Cancer Discovery (2024) Vol. 14, Iss. 10, pp. 1879-1900
Closed Access | Times Cited: 9
Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress
Shigao Cheng, Huiyuan Wang, Xuejia Kang, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 251-251
Open Access | Times Cited: 5
Cancer immunotherapy by γδ T cells
Adrian Hayday, Julie Déchanet‐Merville, Jamie Rossjohn, et al.
Science (2024) Vol. 386, Iss. 6717
Open Access | Times Cited: 5
Exploring CAR-PBMCs: A Novel Strategy Against EGFR-Positive Tumor Cells
Alexandru Tîrziu, Oana-Isabella Gavriliuc, Florina Bojin, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 264-264
Open Access
Follicular Lymphoma: Paving the Path to Cures through Philanthropy
Mitchell R. Smith, Michel Azoulay, Lee M. Greenberger
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy
Alberto J. Millan, Vincent Allain, Indrani Nayak, et al.
The Journal of Immunology (2025)
Closed Access
Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy
Neda Dadgar, Arun Kumar Arunachalam, Hanna Hong, et al.
Cancers (2024) Vol. 16, Iss. 18, pp. 3232-3232
Open Access | Times Cited: 4
Contemporary Approaches to Immunotherapy of Solid Tumors
A. V. Kuznetsova, Ksenia А. Glukhova, О. П. Попова, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2270-2270
Open Access | Times Cited: 3
TALEN-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors while Mitigating Off-Tumor Toxicity
Sonal Dharani, Hana Cho, Jorge Postigo, et al.
Molecular Therapy (2024) Vol. 32, Iss. 11, pp. 3915-3931
Open Access | Times Cited: 3
Harnessing natural killer cell effector function against cancer
Matthew D. Blunt, Salim I. Khakoo
Immunotherapy Advances (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 9
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Minggang Fang, Alexander G. Allen, Chong Luo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
Pin Mei Yao, Yaguang Liu, Gang Huang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Spleen Tyrosine Kinase (SYK) negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy
Alberto J. Millan, Vincent Allain, Indrani Nayak, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The method for assessing the specificity of developing CAR therapies
Ivan V. Prikhodko, Georgy Guria
Biophysical Reports (2024) Vol. 4, Iss. 3, pp. 100172-100172
Open Access
NK cell based immunotherapy against oral squamous cell carcinoma
Ying Zhang, Jianming Xie, Haoran Wu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
HSF1 renders NK cells too stressed to respond
Yael Gruper, Aviad Ben‐Shmuel, Ruth Scherz‐Shouval
Nature Cell Biology (2024) Vol. 26, Iss. 10, pp. 1630-1631
Closed Access
NK Cell‐Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities
Mohammad Y. Alshahrani, Subasini Uthirapathy, Abhinav Kumar, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 11
Closed Access
Advances and challenges in chimeric antigen receptor‐natural killer cell immunotherapy for cancer
Hind Rafei, Katayoun Rezvani
British Journal of Haematology (2024)
Open Access
Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors
Pooya Farhangnia, Hossein Khorramdelazad, Pouria Ghiaee, et al.
Interdisciplinary cancer research (2023)
Closed Access
Golden age of immunoengineering
Wilson W. Wong, Wendell A. Lim
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 4-9
Open Access
Page 1

Scroll to top